| Rivaroxaban - Wikipedia, the free encyclopedia Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer ; in a number of countries it is marketed as Xarelto. In the United States, it ... Read More |
| XARELTO® (rivaroxaban) Official Site Find information on XARELTO® (rivaroxaban). ... About XARELTO ® XARELTO ® is a prescription medicine used to: reduce the risk of stroke and blood clots in people ... Read More |
| Official Site - Information for Healthcare Providers | XARELTO ... Read about XARELTO® (rivaroxaban tablets), its efficacy and safety from multiple well-controlled clinical trials for FDA-approved uses, and view the full US ... Read More |
| Xarelto® - First in Oral, Direct Factor Xa Inhibition (Latest update: 10th May 2012) - Xarelto® (rivaroxaban) is a highly effective, oral anticoagulant developed to prevent and treat dangerous blood clots in a wide ... Read More |
| Rivaroxaban: MedlinePlus Drug Information If you have epidural or spinal anesthesia or a spinal puncture while taking a 'blood thinner' such as rivaroxaban, you are at risk for collecting blood in ... Read More |
| Rivaroxaban, Dabigatran, or Warfarin? November 18, 2011 (Orlando, Florida) — For decades, warfarin has been the best — and pretty much only — oral anticoagulant for stroke prevention in atrial ... Read More |
| Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation ... The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an ... Read More |
| Rivaroxaban (Xarelto) Gains First FDA Approval for DVT Prevention ... Rivaroxaban(Xarelto, Janssen) received FDA approval today for the prevention of deep vein thrombosis which may lead to a pulmonary embolism in patients ... Read More |
| Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons ... Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme Read More |
| Rivaroxaban Redux: Drug Faces Challenges in Approval Process and ... Johnson & Johnson overcame a surprisingly negative Food and Drug Administration staff review of its blood thinner rivaroxaban yesterday to win an advisory ... Read More |
